|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PRTFDC1 |
Gene summary for PRTFDC1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PRTFDC1 | Gene ID | 56952 |
| Gene name | phosphoribosyl transferase domain containing 1 | |
| Gene Alias | HHGP | |
| Cytomap | 10p12.1 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9NRG1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 56952 | PRTFDC1 | LZE24T | Human | Esophagus | ESCC | 1.83e-08 | 2.83e-01 | 0.0596 |
| 56952 | PRTFDC1 | LZE6T | Human | Esophagus | ESCC | 2.86e-02 | 2.75e-01 | 0.0845 |
| 56952 | PRTFDC1 | P2T-E | Human | Esophagus | ESCC | 9.67e-18 | 2.91e-01 | 0.1177 |
| 56952 | PRTFDC1 | P4T-E | Human | Esophagus | ESCC | 5.20e-13 | 2.08e-01 | 0.1323 |
| 56952 | PRTFDC1 | P5T-E | Human | Esophagus | ESCC | 3.60e-13 | 2.40e-01 | 0.1327 |
| 56952 | PRTFDC1 | P8T-E | Human | Esophagus | ESCC | 1.88e-11 | 2.05e-01 | 0.0889 |
| 56952 | PRTFDC1 | P10T-E | Human | Esophagus | ESCC | 1.88e-04 | 9.65e-02 | 0.116 |
| 56952 | PRTFDC1 | P12T-E | Human | Esophagus | ESCC | 6.38e-31 | 5.54e-01 | 0.1122 |
| 56952 | PRTFDC1 | P15T-E | Human | Esophagus | ESCC | 4.47e-20 | 5.10e-01 | 0.1149 |
| 56952 | PRTFDC1 | P16T-E | Human | Esophagus | ESCC | 2.87e-41 | 7.37e-01 | 0.1153 |
| 56952 | PRTFDC1 | P21T-E | Human | Esophagus | ESCC | 2.27e-21 | 3.16e-01 | 0.1617 |
| 56952 | PRTFDC1 | P24T-E | Human | Esophagus | ESCC | 3.28e-14 | 2.30e-01 | 0.1287 |
| 56952 | PRTFDC1 | P26T-E | Human | Esophagus | ESCC | 3.28e-14 | 2.49e-01 | 0.1276 |
| 56952 | PRTFDC1 | P27T-E | Human | Esophagus | ESCC | 4.30e-10 | 1.98e-01 | 0.1055 |
| 56952 | PRTFDC1 | P28T-E | Human | Esophagus | ESCC | 1.78e-03 | 7.91e-02 | 0.1149 |
| 56952 | PRTFDC1 | P31T-E | Human | Esophagus | ESCC | 2.06e-08 | 1.97e-01 | 0.1251 |
| 56952 | PRTFDC1 | P32T-E | Human | Esophagus | ESCC | 1.75e-25 | 4.47e-01 | 0.1666 |
| 56952 | PRTFDC1 | P36T-E | Human | Esophagus | ESCC | 1.96e-03 | 2.06e-01 | 0.1187 |
| 56952 | PRTFDC1 | P37T-E | Human | Esophagus | ESCC | 6.34e-16 | 4.25e-01 | 0.1371 |
| 56952 | PRTFDC1 | P38T-E | Human | Esophagus | ESCC | 2.30e-04 | 1.99e-01 | 0.127 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0072521111 | Esophagus | ESCC | purine-containing compound metabolic process | 238/8552 | 416/18723 | 1.20e-06 | 1.49e-05 | 238 |
| GO:007252217 | Esophagus | ESCC | purine-containing compound biosynthetic process | 120/8552 | 200/18723 | 3.02e-05 | 2.51e-04 | 120 |
| GO:19016574 | Esophagus | ESCC | glycosyl compound metabolic process | 57/8552 | 88/18723 | 2.32e-04 | 1.44e-03 | 57 |
| GO:00091163 | Esophagus | ESCC | nucleoside metabolic process | 39/8552 | 62/18723 | 4.68e-03 | 1.82e-02 | 39 |
| GO:00430941 | Esophagus | ESCC | cellular metabolic compound salvage | 18/8552 | 26/18723 | 1.32e-02 | 4.31e-02 | 18 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PRTFDC1 | SNV | Missense_Mutation | c.30N>A | p.Asp10Glu | p.D10E | Q9NRG1 | protein_coding | tolerated(0.63) | benign(0) | TCGA-C8-A1HF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| PRTFDC1 | SNV | Missense_Mutation | c.175N>T | p.Asp59Tyr | p.D59Y | Q9NRG1 | protein_coding | tolerated(0.09) | possibly_damaging(0.744) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD | |
| PRTFDC1 | SNV | Missense_Mutation | c.577N>G | p.Leu193Val | p.L193V | Q9NRG1 | protein_coding | tolerated(0.41) | benign(0) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| PRTFDC1 | SNV | Missense_Mutation | c.421G>C | p.Glu141Gln | p.E141Q | Q9NRG1 | protein_coding | deleterious(0.01) | possibly_damaging(0.74) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| PRTFDC1 | SNV | Missense_Mutation | novel | c.366G>C | p.Gln122His | p.Q122H | Q9NRG1 | protein_coding | tolerated(0.26) | benign(0.02) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| PRTFDC1 | SNV | Missense_Mutation | c.196N>C | p.Tyr66His | p.Y66H | Q9NRG1 | protein_coding | tolerated(0.51) | benign(0) | TCGA-CK-6746-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PRTFDC1 | SNV | Missense_Mutation | c.293N>A | p.Arg98Gln | p.R98Q | Q9NRG1 | protein_coding | tolerated(0.15) | benign(0.003) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| PRTFDC1 | SNV | Missense_Mutation | novel | c.187N>T | p.Asp63Tyr | p.D63Y | Q9NRG1 | protein_coding | deleterious(0.03) | possibly_damaging(0.568) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| PRTFDC1 | SNV | Missense_Mutation | novel | c.596C>T | p.Ala199Val | p.A199V | Q9NRG1 | protein_coding | deleterious(0) | probably_damaging(0.929) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PRTFDC1 | SNV | Missense_Mutation | rs376854848 | c.281G>A | p.Arg94Gln | p.R94Q | Q9NRG1 | protein_coding | tolerated(0.26) | benign(0.069) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |